Health Catalyst (HCAT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
16 Jul, 2026Opening remarks and agenda
Meeting called to order by General Counsel, conducted as an audio webcast in accordance with bylaws and Delaware law.
Notice and proxy statement mailed to stockholders of record as of May 22, 2026.
Voting procedures and Q&A process explained, with digital access to materials and online voting.
Directors, officers, and independent auditor introduced; stockholders of record entitled to vote.
Board and executive committee updates
Directors present: Ben Albert, Mathew Arens, Dr. Jill Hoggard Green, Justin Spencer.
Officers present: CEO Ben Albert, CFO Jason Alger, General Counsel Ben Landry.
Ernst & Young LLP represented as independent auditor.
Shareholder proposals
Election of two Class I directors for terms ending at the 2029 annual meeting.
Ratification of Ernst & Young LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory, non-binding vote on executive compensation.
Proposal to phase out classified board structure and move to annual director elections after 2029.
Latest events from Health Catalyst
- Q3 2025 revenue flat at $76.3M, Adjusted EBITDA up 64%, net loss widened on non-recurring charges.HCAT
Q3 20258 Jul 2026 - Q3 revenue up 3% to $76.4M, adjusted EBITDA $7.3M, and full-year outlook raised.HCAT
Q3 20248 Jul 2026 - Q2 revenue up 4% to $75.9M, EBITDA rose, net loss narrowed, and record new client growth achieved.HCAT
Q2 20248 Jul 2026 - Q1 revenue up 6% to $79.4M, Adjusted EBITDA rose, Upfront acquired, guidance reiterated.HCAT
Q1 20258 Jul 2026 - Key votes include director elections, auditor ratification, and board structure changes.HCAT
Proxy filing3 Jun 2026 - Board seeks approval for director elections, auditor ratification, executive pay, and declassification.HCAT
Proxy filing3 Jun 2026 - Proxy covers director elections, auditor ratification, say-on-pay, and board declassification.HCAT
Proxy filing19 May 2026 - Q1 2026 saw $70.8M revenue, $9.1M adjusted EBITDA, and a $95.5M goodwill impairment widening net loss.HCAT
Q1 202611 May 2026 - 2025 revenue rose 1% to $311.1M, but net loss deepened on large impairment charges.HCAT
Q4 20253 May 2026